SymBiosis

What SymBiosis does

SymBiosis Capital Management, LLC is a privately held, biotechnology-focused venture capital firm headquartered in Bentonville, Arkansas, founded in 2021. The firm invests across financing stages from seed through public companies in cutting-edge biotherapeutic platforms, targeting life-threatening diseases with hard endpoints, modality-agnostic novel platforms, leads reaching human proof-of-concept within the investment horizon, and designs amenable to scalable manufacturing. As of the input, the firm manages a portfolio of more than 30 investments (26 listed on its website) spanning modalities including radiopharmaceuticals (AdvanCell), ADCs (Parabilis, Solve), RNAi (SanegeneBio), mRNA (Kernal), xenotransplantation (eGenesis), microbiome therapeutics (Finch, Siolta, Enterome), and cardiometabolic small molecules (Corxel, Endeavor).

The investment process is sales-led and highly structured: sourcing through a public submission funnel and operating-advisor network, initial calls with targets and key opinion leaders, data room review, financial modeling, and investment memo writing, with post-close board representation and monitoring. The firm has a China-nexus capability via a dedicated Business Development Lead and an Asia-focused Operating Advisor, and co-invests with tier-1 specialist biotech VCs (Abingworth, F-Prime, RA Capital, SR One, TCGX, HBM, SV Health, Sanofi Ventures). As a VC firm, revenue derives from management fees on committed capital and carried interest on successful investments rather than product sales.

The 17-person team combines a Managing Partner with private credit and impact investing background, several PhDs and MDs in investments and AI/analytics, and Operating Advisors with prior senior roles at Amgen, Novartis, AstraZeneca, Kite Pharma, Metsera, Samsung Biologics, UBS, Goldman Sachs, and Mayo Clinic. The firm has built an internal AI & Analytics function that creates cloud-based tools and automation to support investment diligence and portfolio operations across the firm.

Name

SymBiosis

Legal name

SymBiosis Capital Management, LLC

Website

https://symbiosis.vc

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

SymBiosis is a privately held, biotechnology-focused venture capital firm that invests across stages from seed to public in biotherapeutic platforms targeting life-threatening diseases with hard endpoints, currently managing 30+ portfolio investments from Bentonville, Arkansas.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Management Consulting Services (54161)

SIC

Miscellaneous Business Credit Institution (6159)

akta.pro primary industry

Large-Cap / Sponsor Finance Direct Lending (FSANADAJ)

Keywords

• Venture capital
• Biotech investments
• Life sciences venture capital
• Biopharmaceutical funding
• Private equity

Headquarters

HQ city

Bentonville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Venture Capital Returns: SymBiosis generates returns through investment in biotechnology companies. As a VC firm, revenue comes from carried interest on successful investments and management fees on committed capital.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

SymBiosis Capital Management is a biotechnology-focused venture capital firm that invests in cutting-edge biotherapeutic companies across financing stages from seed through public investments. The firm partners with innovators building groundbreaking companies targeting life-threatening diseases with novel therapeutic platforms, leading candidates reaching human proof-of-concept, and designs for manufacturability. The firm manages a portfolio of more than 30 investments with significant long-term capital commitments and operates a dedicated Business Development Lead for China-nexus sourcing.

Differentiator

Problem solved

Functional benefit

Products and services

• SymBiosis Capital Management Investment Services Venture capital investment services targeting cutting-edge biotherapeutic companies across financing stages from seed through public investments. The firm invests in companies developing life-threatening disease treatments with novel therapeutic platforms, leads reaching human proof-of-concept within the investment horizon, and designs for manufacturability. Available to accredited investors through offering documents.

Quantifiable outcome

• 30+ portfolio investments
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Sol BabaniminorOthersSol Babani is founder and CEO of Symbiosis Advisors (a separate entity from SymBiosis Capital Management), appointed as Strategic Advisor to AMC Health's DCT business.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Atlas Venture: Early-stage biotech venture firm investing across modalities from seed to clinical proof-of-concept. Directly comparable in stage focus, modality-agnostic philosophy, and life-threatening disease orientation, with a much longer track record of exits.
• ARCH Venture Partners: Pioneer biotech VC investing in early-stage platform companies and complex science. SymBiosis's modality-agnostic, manufacturability-focused thesis is highly comparable to ARCH's approach to backing technically ambitious therapeutic platforms.
• Versant Ventures: Healthcare-focused venture firm with biotech, medtech, and specialty pharma strategies. Comparable in stage focus (early to clinical) and therapeutic breadth across modalities.
• 5AM Ventures: Early-stage life sciences VC investing in platform technologies and therapeutic companies. Similar stage focus and modality-agnostic approach; comparable portfolio breadth across small molecules, biologics, and novel modalities.
• RA Capital Management: Healthcare-focused investment firm with crossover and private equity strategies. Direct competitor in biotech private investing; co-invested with SymBiosis in Corxel's $287M Series D1 round.
• Abingworth: Life sciences-focused investment firm with crossover, venture, and private equity strategies. Direct competitor and frequent co-investor; co-led AdvanCell Series C and R1 Therapeutics Series A with SymBiosis.
• F-Prime Capital: Global venture capital firm investing across healthcare and technology with strong biotech franchise. Direct biotech competitor; co-led R1 Therapeutics' $77.5M Series A alongside SymBiosis.
• OrbiMed Advisors: Largest healthcare-dedicated investment firm globally with public and private strategies. Direct competitor across all stages of biotech private investing from venture through growth.
• Longitude Capital: Healthcare-focused venture capital firm investing in development-stage therapeutics, medical devices, and diagnostics. Highly comparable in stage focus and biotech specialization.

Broad incumbents

• New Enterprise Associates (NEA): Large multi-stage venture firm with significant biotech and healthcare practice. Broader investor with overlap in biotech venture but operates across many technology and consumer sectors; not specialized to biotech alone.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/symbiosiscapitalmanagement

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments24 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SymBiosis